In successful clinical trials of drugs for inflammatory bowel disease (IBD), patients who received a placebo were at significantly higher risk for potential harms, according to two systematic reviews.

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...

Up to 3.1 million people live with inflammatory bowel disease (IBD), which includes gastrointestinal disorders such as ulcerative colitis (UC) and Crohn’s disease that cause inflammation in the ...

The following is a summary of "AI-driven Personalized Medicine: Transforming Clinical Practice in Inflammatory Bowel Disease, ...

If you would like to request a paper copy of the toolkit, contact the AWARE-IBD team ([email protected]). Daniel Hind CTRU Oversight Clinical Trials Research Unit, University of Sheffield ...

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

A simple stool test may reveal why some people are sensitive to food emulsifiers such as CMC, offering insights into IBD risk ...

Through use of precision medicine and machine learning (ML), the company’s cell-centred models will aid identification of patient subtypes and pair them with personalised IBD targets.

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, ...